OSE Immunotherapeutics SA, a clinical-stage biotechnology company specializing in the development of immunotherapies, has recently announced significant developments in its research and clinical trials. The company, headquartered in Nantes, France, operates within the Health Care sector, specifically in the Biotechnology industry. Listed on the NYSE Euronext Paris, OSE Immunotherapeutics has a market capitalization of 69,336,776 EUR, with a close price of 3.024 EUR as of April 23, 2026. Despite a challenging financial year, evidenced by a negative price-to-earnings ratio of -1.91, the company continues to make strides in its clinical endeavors.
One of the company’s key projects, Tedopi®, a neo-epitope vaccine, is currently in a Phase 2 study known as the TEDOVA trial. This study focuses on platinum-sensitive recurrent ovarian cancer and involves 185 patients. The trial evaluates the efficacy of Tedopi® administered alone or in combination with the PD-1 inhibitor pembrolizumab, compared to best supportive care following standard chemotherapy, bevacizumab, and a PARP inhibitor. The topline results of this study are set to be presented orally at the 2026 American Society of Clinical Oncology (ASCO) meeting in Chicago. Dr. Alexandra Leary of Gustave Roussy will lead the presentation, highlighting progression-free survival outcomes.
OSE Immunotherapeutics’ pipeline includes several promising therapies. Tedopi® is also in a Phase III clinical trial for non-small cell lung cancer and a Phase II trial for pancreatic and ovarian cancer. Additionally, OSE-279, a Phase I/II clinical trial candidate, targets advanced solid tumors or lymphomas. The company is developing OSE-127, a humanized monoclonal antibody in Phase II for ulcerative colitis and Sjögren’s Syndrome, and FR104 for rheumatoid arthritis in Phase I. Other notable projects include BI 765063 for solid tumors, OSE-230, an agonist antibody against ChemR23, CLEC-1 monoclonal antibody antagonists, and BiCKI, a bispecific checkpoint inhibitor targeting PD-1.
OSE Immunotherapeutics has established collaborations with several prestigious institutions and companies, including GERCOR, ARCAGY-GINECO, Foundation FoRT, Nantes University Hospital, Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. These partnerships are instrumental in advancing the company’s research and development efforts.
Founded in 2012 and formerly known as OSE Pharma SA, the company rebranded to OSE Immunotherapeutics SA in May 2016. Its commitment to pioneering first-in-class immuno-oncology and immuno-inflammation therapies continues to drive its research and clinical trials forward. For further information, the company’s latest disclosures are accessible through its website and investor relations channels.
